MCID: HRP004
MIFTS: 58

Herpes Zoster

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Herpes Zoster

MalaCards integrated aliases for Herpes Zoster:

Name: Herpes Zoster 12 75 25 54 55 44 15 17
Shingles 12 75 25 54 43 3 63
Herpes Zoster Disease 72
Herpes Zona 12
Zoster 25

Classifications:



External Ids:

Disease Ontology 12 DOID:8536
ICD9CM 35 053
MeSH 44 D006562
NCIt 50 C71079
SNOMED-CT 68 4740000
UMLS 72 C0019360

Summaries for Herpes Zoster

MedlinePlus : 43 What is shingles? Shingles is an outbreak of rash or blisters on the skin. It is caused by the varicella-zoster virus - the same virus that causes chickenpox. After you have chickenpox, the virus stays in your body. It may not cause problems for many years. But as you get older, the virus may reappear as shingles. Is shingles contagious? Shingles is not contagious. But you can catch chickenpox from someone with shingles. If you've never had chickenpox or the chickenpox vaccine, try to stay away from anyone who has shingles. If you have shingles, try to stay away from anyone who has not had chickenpox or the chickenpox vaccine, or anyone who might have a weak immune system. Who is at risk for shingles? Anyone who has had chickenpox is at risk for getting shingles. But this risk goes up as you get older; shingles is most common in people over age 50. People with weakened immune systems are at higher risk of getting shingles. This includes those who Have immune system diseases such as HIV/AIDS Have certain cancers Take immunosuppressive drugs after an organ transplant Your immune system may be weaker when you have an infection or are stressed. This can raise your risk of shingles. It is rare, but possible, to get shingles more than once. What are the symptoms of shingles? Early signs of shingles include burning or shooting pain and tingling or itching. It is usually on one side of the body or face. The pain can be mild to severe. One to 14 days later, you will get a rash. It consists of blisters that typically scab over in 7 to 10 days. The rash is usually a single stripe around either the left or the right side of the body. In other cases, the rash occurs on one side of the face. In rare cases (usually among people with weakened immune systems), the rash may be more widespread and look similar to a chickenpox rash. Some people may also have other symptoms: Fever Headache Chills Upset stomach What are the complications of shingles? Shingles can cause complications: Postherpetic neuralgia (PHN) is most common complication of shingles. It causes severe pain in the areas where you had the shingles rash. It usually gets better in a few weeks or months. But some people can have pain from PHN for many years, and it can interfere with daily life. Vision loss can happen if shingles affects your eye. It may be temporary or permanent. Hearing or balance problems are possible if you have shingles within or near your ear. You may also have weakness of the muscles on that side of your face. These problems can be temporary or permanent. Very rarely, shingles can also lead to pneumonia, brain inflammation (encephalitis), or death. How is shingles diagnosed? Usually your health care provider can diagnose shingles by taking your medical history and looking at your rash. In some cases, your provider may scrap off tissue from the rash or swab some fluid from the blisters and send the sample to a lab for testing. What are the treatments for shingles? There is no cure for shingles. Antiviral medicines may help to make the attack shorter and less severe. They may also help prevent PHN. The medicines are most effective if you can take them within 3 days after the rash appears. So if you think you might have shingles, contact your health care provider as soon as possible. Pain relievers may also help with the pain. A cool washcloth, calamine lotion, and oatmeal baths may help relieve some of the itching. Can shingles be prevented? There are vaccines to prevent shingles or lessen its effects. The Centers for Disease Control and Prevention recommends that healthy adults 50 years and older get the Shingrix vaccine. You need two doses of the vaccine, given 2 to 6 months apart. Another vaccine, Zostavax, may be used in certain cases.

MalaCards based summary : Herpes Zoster, also known as shingles, is related to uveitis and variola major, and has symptoms including fever, paresthesia and headache. An important gene associated with Herpes Zoster is DPYD (Dihydropyrimidine Dehydrogenase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Foscarnet and Capsaicin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotype is neoplasm.

Disease Ontology : 12 A viral infectious disease that results in infection located in nerve fiber, has material basis in Human herpesvirus 3, which reactivates after appearing as chickenpox in childhood. The virus is transmitted by direct contact with the rash, which can develop into chickenpox in newly-infected individuals. The infection has symptom rash which is followed by blisters, has symptom headache, has symptom fever, has symptom malaise, has symptom itching, has symptom burning pain, and has symptom paresthesia.

Genetics Home Reference : 25 Shingles (also known as herpes zoster) results from infection by the varicella zoster virus. This common virus causes chickenpox (also known as varicella), which is characterized by itchy spots on the skin that cover the whole body and usually occurs in childhood or adolescence. After the body fights the initial infection, the varicella zoster virus remains in nerve cells for the rest of a person's life. Because the virus is controlled by immune system cells called T cells, it is generally inactive (latent) and typically causes no health problems. However, in some people, the virus becomes active again (reactivates) and causes shingles. Shingles can occur at any age, although it is rare in childhood and becomes more common after age 50. Shingles is characterized by a severely painful, itchy, or tingling rash, most commonly on one side of the torso, although it can occur anywhere on the body. Reactivation of the virus usually occurs in a single nerve, leading to the symptoms of shingles in just the region of skin connected to that nerve. When the nerve connected to the eye and the skin surrounding it is affected, the condition is called herpes zoster ophthalmicus. This form of shingles, which accounts for about 20 percent of cases, can cause permanent vision impairment. Some individuals with shingles feel throbbing or tingling in the affected region shortly before the rash appears. Blisters form in the rash area, break open, and scab over in a few days. Healing usually takes 2 to 4 weeks. Most people have only one episode of shingles, although it can recur in rare cases. In 5 to 20 percent of people with shingles, severe pain continues in the affected region after healing of the rash, which is known as postherpetic neuralgia (PHN). PHN is the most common complication of shingles. It can also involve severe itchiness or an overactive pain response to things that do not usually cause pain (allodynia), such as a light touch. PHN can last weeks, months, or even years. The likelihood of developing PHN after shingles and its severity increase with age. The pain caused by shingles and PHN can disrupt day-to-day activities and reduce a person's quality of life.

CDC : 3 Shingles is a painful rash that usually develops on one side of the body, often the face or torso. The rash consists of blisters that typically scab over in 7 to 10 days and clears up within 2 to 4 weeks. Some people describe the pain as an intense burning sensation. For some people, the pain can last for months or even years after the rash goes away. This long-lasting pain is called postherpetic neuralgia (PHN), and it is the most common complication of shingles. Your risk of getting shingles and PHN increases as you get older. Two vaccines are licensed and recommended to prevent shingles in the U.S.. Zoster vaccine live (ZVL, Zostavax) has been in use since 2006. Recombinant zoster vaccine (RZV, Shingrix), has been in use since 2017 and is recommended by ACIP as the preferred shingles vaccine

NINDS : 54 Shingles (herpes zoster) is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chickenpox — the varicella-zoster virus. The first sign of shingles is often burning or tingling pain (which can be severe), or sometimes numbness or itch,generally on one side of the body. After several days or a week, a rash of fluid-filled blisters, similar to chickenpox, appears in one area on one side of the body. Shingles pain can be mild or intense.  Some people have mostly itching; some feel pain from the gentlest touch or breeze.  The most common location for shingles is a band, called a dermatome, spanning one side of the trunk around the waistline. Anyone who has had chickenpox is at risk for shingles.  Scientists think that some of the virus particles from the original exposure to the varicella-zoster virus,leave the skin blisters and move into the nervous system.  When the varicella-zoster virus reactivates, the virus moves back down the long nerve fibers that extend from the sensory cell bodies to the skin.  The viruses multiply, the tell-tale rash erupts, and the person now has shingles.

PubMed Health : 63 About shingles: Anyone who has already had chickenpox is at risk of developing shingles later on. Both are caused by the same virus, the varicella-zoster virus. This virus stays dormant (inactive) in the body after a chickenpox infection. But it can become active again years later and cause shingles (herpes zoster): a rash with blisters that usually forms a band across the skin and is often very painful. The rash normally only affects one side of the body. People who have been vaccinated against chickenpox can still get shingles. But this is thought to be less common than developing it after having chickenpox. Shingles is particularly common in older people. Although it can be very unpleasant, it’s usually over in about two to four weeks if there are no complications. Shingles is contagious, but only for people who have never had chickenpox. In that case the infection only causes chickenpox, and not shingles.

Wikipedia : 75 Shingles, also known as zoster or herpes zoster, is a viral disease characterized by a painful skin rash... more...

Related Diseases for Herpes Zoster

Diseases related to Herpes Zoster via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1039)
# Related Disease Score Top Affiliating Genes
1 uveitis 31.6 IL10 IFNG IFNA2
2 variola major 31.0 IL2 IFNG
3 chronic graft versus host disease 31.0 IL10 IFNG
4 folliculitis 30.9 IFNG FCGR3A
5 discoid lupus erythematosus 30.9 IL10 IFNA2
6 inflammatory bowel disease 30.9 IL2 IL10 IFNG
7 ulcerative colitis 30.8 IL2 IL10 IFNG
8 neutropenia 30.8 IFNA2 FCGR3A DPYD
9 pulmonary tuberculosis 30.7 IL2 IL10 IFNG
10 colitis 30.6 IL2 IL10 IFNG
11 crohn's colitis 30.5 IL2 IFNG
12 autoimmune disease 30.5 IL2 IL10 IFNG COL17A1
13 poliomyelitis 30.5 IL10 IFNG FCGR3A
14 toxic shock syndrome 30.4 IL2 IL10 IFNG
15 tetanus 30.4 IL2 IL10 IFNG
16 leprosy 3 30.4 IL2 IL10 IFNG
17 visceral leishmaniasis 30.3 IL2 IL10 IFNG
18 hand, foot and mouth disease 30.2 IL10 IFNG
19 graft-versus-host disease 30.1 IL2 IL10 IFNG HLA-A
20 acute graft versus host disease 30.1 IL2 IL10 IFNG
21 lepromatous leprosy 30.1 IL2 IL10 IFNG
22 hematopoietic stem cell transplantation 30.1 IL2 IL10 IFNG HLA-A
23 schistosomiasis 30.1 IL2 IL10 IFNG
24 connective tissue disease 30.1 TRPV1 IL10 IFNG
25 common variable immunodeficiency 30.1 IL2 IL10 IFNG
26 erythema multiforme 30.0 IL2 IFNG
27 dermatitis, atopic 30.0 IL2 IL10 IFNG
28 fixed drug eruption 30.0 IL2 IFNG
29 histoplasmosis 30.0 IFNG HLA-A
30 posterior uveitis 30.0 IL2 IFNG
31 aphthous stomatitis 29.9 IL2 IL10 HLA-A
32 mycoplasma pneumoniae pneumonia 29.8 IL10 IFNG
33 burning mouth syndrome 29.8 TRPV1 IL2
34 toxoplasmosis 29.8 IL10 IFNG CCR5
35 multiple sclerosis 29.8 IL2 IL10 IFNG CCR5
36 stevens-johnson syndrome/toxic epidermal necrolysis 29.8 IL2 IFNG HLA-A
37 mouth disease 29.7 TRPV1 IL10 IFNG
38 nervous system disease 29.7 TRPV1 IL10 IFNG
39 systemic lupus erythematosus 29.6 IL2 IL10 IFNG FCGR3A CCR5
40 myasthenia gravis 29.4 TMPO IL2 IL10 IFNG
41 human immunodeficiency virus infectious disease 29.4 IL2 IL10 IFNG CCR5
42 pulmonary sarcoidosis 29.3 IL2 IFNG CCR5
43 bone inflammation disease 29.3 TRPV1 IL2 IL10 IFNG
44 gastrointestinal system disease 29.3 TRPV1 IL2 IL10 IFNG
45 human immunodeficiency virus type 1 29.2 IL2 IL10 IFNG HLA-A CCR5
46 cytomegalovirus retinitis 29.1 IFNG HLA-A CCR5
47 acquired immunodeficiency syndrome 29.1 IL2 IL10 IFNG IFNA2 HCP5 CCR5
48 central nervous system disease 28.9 TRPV1 IFNG CCR5
49 viral infectious disease 28.6 IL2 IL10 IFNG IFNA2 CCR5
50 geniculate herpes zoster 13.1

Graphical network of the top 20 diseases related to Herpes Zoster:



Diseases related to Herpes Zoster

Symptoms & Phenotypes for Herpes Zoster

Symptoms:

12
  • fever
  • paresthesia
  • headache
  • malaise
  • itching
  • rash which is followed by blisters
  • burning pain

UMLS symptoms related to Herpes Zoster:


seizures, tremor, fever, angina pectoris, pruritus, back pain, pain, headache, syncope, chronic pain, sciatica, exanthema, vertigo/dizziness, equilibration disorder, sleeplessness

MGI Mouse Phenotypes related to Herpes Zoster:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 CCR5 IFNG IL10 IL2 TRPV1

Drugs & Therapeutics for Herpes Zoster

PubMed Health treatment related to Herpes Zoster: 63

Pain and fever can be relieved with medication such as acetaminophen (paracetamol) or acetylsalicylic acid (the drug in medicines like Aspirin). Prescription painkillers are sometimes used to relieve more severe pain. Thorough skin care is recommended if you have shingles. Antiseptic or anti-itch lotions, gels and powders are often used to relieve the itching and dry out the blisters. Most of them contain tanins, zinc, menthol or polidocanol. If blisters have already formed, people are sometimes advised to use cooling wraps. But there’s no good scientific research on how well these treatments work. Drugs that fight viruses can be used in people who are over 50 or have a weakened immune system, if the condition is very severe, affects the head and neck area, or there is a higher risk of complications. This is known as "antiviral therapy." Using antiviral medication early on can help speed up recovery and make the pain go away faster. So people are advised to start antiviral therapy no later than 72 hours after the rash starts. In severe cases the medicine can also be given through a drip into a vein (intravenous infusion). If the ear is affected, steroids are often used too. But it still isn’t clear what pros and cons this kind of combination therapy may have.

Drugs for Herpes Zoster (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 252)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
2
Capsaicin Approved Phase 4 404-86-4 1548943
3
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Budesonide Approved Phase 4 51333-22-3 63006 5281004
6
leucovorin Approved Phase 4 58-05-9 143 6006
7
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
8
Interferon beta-1b Approved Phase 4 145155-23-3
9
Tofacitinib Approved, Investigational Phase 4 477600-75-2
10 Vedolizumab Approved Phase 4 943609-66-3
11
Mercaptopurine Approved Phase 4 50-44-2 667490
12
Certolizumab pegol Approved Phase 4 428863-50-7
13
Azathioprine Approved Phase 4 446-86-6 2265
14
Adalimumab Approved Phase 4 331731-18-1 16219006
15
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
18
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
21 Reverse Transcriptase Inhibitors Phase 4
22 Antipruritics Phase 4
23 Dermatologic Agents Phase 4
24 Cyclooxygenase 2 Inhibitors Phase 4
25 Nucleic Acid Synthesis Inhibitors Phase 4
26 Respiratory System Agents Phase 4
27 calcium channel blockers Phase 4
28 Calcium, Dietary Phase 4
29 Anti-Asthmatic Agents Phase 4
30 Bronchodilator Agents Phase 4
31 Folic Acid Antagonists Phase 4
32 Folate Phase 4
33 Vitamin B9 Phase 4
34 Vitamin B Complex Phase 4
35 Fingolimod Hydrochloride Phase 4
36 MF59 oil emulsion Phase 4
37 (T,G)-A-L Phase 4
38 Interferon-beta Phase 4
39
Glatiramer Acetate Phase 4 147245-92-9 3081884
40 interferons Phase 4
41 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
42 Mesalamine Phase 4 89-57-6
43 Central Nervous System Depressants Phase 4
44 Peripheral Nervous System Agents Phase 4
45 Anesthetics, Local Phase 4
46 Anesthetics Phase 4
47 Protein Kinase Inhibitors Phase 4
48 polysaccharide-K Phase 4
49 Janus Kinase Inhibitors Phase 4
50
Methylene blue Approved, Investigational Phase 3 61-73-4

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China Unknown status NCT02151240 Phase 4 Foscarnet Sodium;Acyclovir
2 Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations Unknown status NCT00940940 Phase 4
3 A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya. Unknown status NCT02514018 Phase 4
4 Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine Unknown status NCT02146469 Phase 4
5 Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination Unknown status NCT01866566 Phase 4
6 Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination Unknown status NCT01830283 Phase 4
7 An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
8 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
9 T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape Completed NCT01911065 Phase 4
10 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
11 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
12 An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea Completed NCT01556451 Phase 4
13 A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age Completed NCT00550745 Phase 4
14 An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old. Completed NCT00681031 Phase 4
15 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
16 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
17 Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy Completed NCT00641446 Phase 4 budesonide;varicella zoster virus
18 The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children Completed NCT01138215 Phase 4
19 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
20 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
21 A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine Completed NCT02173899 Phase 4
22 Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina Completed NCT00830648 Phase 4
23 Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin Completed NCT01684072 Phase 4
24 A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
25 A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Completed NCT02187055 Phase 4 Tofacitinib with methotrexate;Tofacitinib without methotrexate
26 Live Attenuated Varicella Vaccine: A New Effective Adjuvant Weapon in the Battlefield Against Severe Resistant Psoriasis, a Randomized Controlled Trial Completed NCT01356004 Phase 4 live attenuated chicken pox vaccine;saline, efficacy
27 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
28 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
29 A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS) Completed NCT01623596 Phase 4 Fingolimod;Disease Modifying therapy
30 Immune Response to Shingles Vaccination Recruiting NCT02624375 Phase 4 Zoster Vaccine Live
31 Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus Recruiting NCT03134196 Phase 4 Masked Placebo;Masked Oral Valacyclovir
32 Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation Recruiting NCT03493776 Phase 4
33 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Recruiting NCT03016884 Phase 4
34 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
35 Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia and for the Prevention of Post Herpetic Neuralgia- a Randomized Controlled Trial Recruiting NCT03809702 Phase 4 Pregabalin;Placebo
36 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
37 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Recruiting NCT03330171 Phase 4
38 A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors Active, not recruiting NCT02444936 Phase 4 ZOSTAVAX
39 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Active, not recruiting NCT02477150 Phase 4
40 Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study) Active, not recruiting NCT02868970 Phase 4
41 Safety and Immunogenicity of Recombinant Glycoprotein E Herpes Zoster Subunit (HZ/su) Vaccine in Renal Transplant Recipients Not yet recruiting NCT03993717 Phase 4
42 The Immunogenicity and Efficacy of Subunit Vaccine Against Herpes Zoster in RA Treated With JAK-inhibitors (VACCIMIL-ZOSTER) Not yet recruiting NCT03886038 Phase 4
43 Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine Not yet recruiting NCT02026089 Phase 4
44 Does Stellate Ganglion Blockade (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes? A Pilot Prospective Cohort Study Not yet recruiting NCT03796195 Phase 4 .5% Bupivacaine
45 A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy Terminated NCT02408159 Phase 4 Varicella Zoster Vaccine;Placebo
46 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
47 Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation Unknown status NCT00213304 Phase 3
48 Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland Unknown status NCT00492739 Phase 2, Phase 3
49 Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery Unknown status NCT00926419 Phase 2, Phase 3
50 Thoracic Epidural Morphine Versus Triamcinolone Acetonide Analgesia in Flail Chest Unknown status NCT03413059 Phase 2, Phase 3 Morphine Sulfate;Triamcinolone Acetonide

Search NIH Clinical Center for Herpes Zoster

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acyclovir
Acyclovir
Acyclovir Sodium
CAPSACIAN PWDR
Capsaicin
CAPSAICIN PWDR
Capsicum extract
CAPSICUM OLEORESIN
famciclovir
Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Ox bile extract
Valaciclovir
valacyclovir
Valacyclovir hydrochloride
Varicella Zoster Vaccine (Live/Attenuated)
Varicella Zoster Vaccine (Recombinant)

Cochrane evidence based reviews: herpes zoster

Genetic Tests for Herpes Zoster

Anatomical Context for Herpes Zoster

MalaCards organs/tissues related to Herpes Zoster:

41
Skin, Eye, T Cells, Testes, Bone, Bone Marrow, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Zoster:

19
Nerve Fiber

Publications for Herpes Zoster

Articles related to Herpes Zoster:

(show top 50) (show all 9402)
# Title Authors PMID Year
1
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. 38 17
31287523 2019
2
Real-world database investigating the association between diabetes mellitus and herpes zoster in Taiwan. 38 17
31045823 2019
3
Update in Herpes Zoster Prevention and the Role of Dermatologists 38 17
30681788 2019
4
Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus. 9 38
14593495 2005
5
Chronic varicella-zoster virus skin lesions in patients with human immunodeficiency virus are related to decreased expression of gE and gB. 9 38
9207378 1997
6
The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. 9 38
9164418 1997
7
Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. 9 38
1569421 1992
8
[Therapeutic indications in herpes zoster]. 9 38
1828198 1991
9
Recovery of ocular and cervical vestibular evoked myogenic potentials after treatment of inner ear diseases. 38
31070081 2019
10
Ramsay Hunt syndrome: a rare complication of herpes zoster infection in a lung cancer patient. 38
30189789 2019
11
VZV-containing vaccines and hospitalization for herpes zoster: careful optimism. 38
31317517 2019
12
Practical points for applying herpes zoster vaccine recommendations. 38
31436592 2019
13
Leukemia cutis following herpes zoster infection: An unusual example of Wolf's isotopic response. 38
31389376 2019
14
Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015. 38
31168709 2019
15
Herpes zoster of the external ear. 38
30604491 2019
16
Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). 38
29619848 2019
17
Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review. 38
30913912 2019
18
Herpes zoster-associated paresis of the left arm. 38
30552696 2019
19
Herpes Zoster after Recombinant Zoster Vaccine: A First Case Report. 38
31377436 2019
20
In reply-Vascular Event Risk After Herpes Zoster. 38
31378245 2019
21
Herpes zoster ophthalmicus pseudodendrites: For topical antivirals or not? 38
30850997 2019
22
RF-New Recombinant Vaccine for the Prevention of Herpes Zoster. 38
31387689 2019
23
The changing epidemiology of herpes zoster over a decade in South Korea, 2006-2015. 38
31377077 2019
24
Herpes zoster in people who are immunocompromised: what are the options for prevention? 38
31399376 2019
25
Low level of hemoglobin A1c and the increased incidence of herpes zoster: longitudinal study. 38
31111373 2019
26
The essential role of pharmacists facilitating vaccination in older adults: the case of Herpes Zoster. 38
31369322 2019
27
Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data. 38
31392326 2019
28
Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. 38
30617027 2019
29
Neurologic Acyclovir Toxicity in the Absence of Kidney Injury. 38
31171414 2019
30
Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis. 38
31004745 2019
31
Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). 38
31394276 2019
32
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 38
31413005 2019
33
Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case. 38
30897230 2019
34
Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002-2016. 38
31436814 2019
35
Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. 38
31318605 2019
36
Reply letter: trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015. 38
31311411 2019
37
Ten years of experience with herpes zoster vaccine in primary care- how attitudes and practices have changed and what it may mean for a new zoster vaccine. 38
31400911 2019
38
Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. 38
31301920 2019
39
Predicting Human Infection Risk: Do Rodent Host Resistance Models Add Value? 38
31106824 2019
40
Infectious complications in the Southern Tasmanian kidney transplant population. 38
30152077 2019
41
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. 38
31399378 2019
42
Estradiol Acts in Lateral Thalamic Region to Attenuate Varicella Zoster Virus Associated Affective Pain. 38
31271831 2019
43
Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study. 38
31376333 2019
44
The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors. 38
31401212 2019
45
Case of herpes zoster with herpetic folliculitis complicated with meningitis: Immunohistochemistry. 38
30888068 2019
46
Fifty Years in Search of Selective Antiviral Drugs. 38
30939009 2019
47
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. 38
31399377 2019
48
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study. 38
31410787 2019
49
Ultrasound-guided peri-brachial plexus polydeoxyribonucleotide injection for a patient with postherpetic brachial plexopathy: A case report. 38
31374058 2019
50
Multidermatomal Herpes Zoster in immunocompromised patient. 38
31422652 2019

Variations for Herpes Zoster

Expression for Herpes Zoster

Search GEO for disease gene expression data for Herpes Zoster.

Pathways for Herpes Zoster

Pathways related to Herpes Zoster according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 IL2 IL10 IFNG IFNA2 HLA-A CCR5
2
Show member pathways
12.73 IL2 IL10 IFNG IFNA2 HLA-A CD8A
3 12.39 IL2 IL10 IFNG CD8A
4
Show member pathways
12.37 IL2 IL10 IFNG CD8A CCR5
5
Show member pathways
12.35 IL2 IFNG IFNA2 HLA-A FCGR3A
6
Show member pathways
12.22 IL2 IL10 IFNG IFNA2 CCR5
7
Show member pathways
12.14 IL10 IFNG FCGR3A CCR5
8
Show member pathways
12.14 IL2 IL10 IFNG IFNA2 HLA-A
9 12.1 IL10 IFNG IFNA2 FCGR3A
10 11.9 HLA-A FCGR3A CD8A
11
Show member pathways
11.88 IL2 IL10 IFNG
12 11.62 IL2 IL10 IFNG IFNA2 CD8A
13 11.61 IL2 IL10 IFNG CD8A
14 11.6 IL2 IL10 IFNG IFNA2 CCR5
15 11.52 IL2 IL10 IFNG FCGR3A
16
Show member pathways
11.41 IL2 IFNG HLA-A CD8A
17
Show member pathways
11.41 IL2 IFNG HLA-A CD8A CCR5
18 11.4 IL2 IL10 IFNG
19 11.16 IL2 IL10 IFNG
20 11.1 IL2 CD8A
21 11.09 IL2 IL10 IFNG
22 11.05 IL2 IFNG
23 10.89 IL2 IL10 IFNG IFNA2 CD8A

GO Terms for Herpes Zoster

Cellular components related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 TRPV1 FCGR3A CD8A CCR5

Biological processes related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.71 TRPV1 IL10 IFNA2 CCR5
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.65 TRPV1 IL2 CCR5
3 cytokine-mediated signaling pathway GO:0019221 9.62 IL2 IL10 IFNA2 CCR5
4 defense response GO:0006952 9.46 IFNA2 CCR5
5 regulation of immune response GO:0050776 9.46 HLA-A FCGR3A COL17A1 CD8A
6 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNG IFNA2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 IL2 IFNG IFNA2
8 regulation of regulatory T cell differentiation GO:0045589 9.37 IL2 IFNG
9 cell surface receptor signaling pathway GO:0007166 9.35 TRPV1 IFNG IFNA2 CD8A CCR5
10 immune response GO:0006955 9.17 IL2 IL10 IFNG HLA-A FCGR3A CD8A

Molecular functions related to Herpes Zoster according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL2 IL10 IFNG IFNA2

Sources for Herpes Zoster

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....